Skip to main content

Table 2 Characteristics of studies and the schedule of drug administration among the included studies

From: Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial

Study

Cases

Sex(M/F)

Age (year)

Type of patients

Stage

Grade

Comparison

Dosage of intervention

Follow-up

Dong 2017 [16]

28

NA

NA

NMIBC

NA

NA

GEM

1000 mg weekly for 8 weeks followed by monthly instillations

12 months

MMC

20 mg weekly for 8 weeks followed by monthly instillations

Lin 2016 [17]

84

56/28

GEM:61 ± 4.2

MMC:62 ± 3.5

NMIBC

Tis: 3

Ta: 24

T1: 59

G1: 40 G2: 27

G3: 17

GEM

1000 mg weekly for 8 weeks followed by monthly instillations (a total of 1 year or 2 years)

24 months

MMC

30 mg weekly for 8 weeks followed by monthly instillations (a total of 1 year or 2 years)

Sun 2016 [18]

58

45/13

GEM: 37 ~ 83

MMC: 31 ~ 81

NMIBC

NA

NA

GEM

1000 mg weekly for 8 weeks followed by 10 monthly instillations (a total of 1 year)

2 years

MMC

20 mg weekly for 8 weeks followed by 10 monthly instillations (a total of 1 year)

Xiaohong 2015 [19]

56

45/11

GEM:51.26 ± 13.42

MMC:51.64 ± 12.39

NMIBC

Tis: 1

Ta: 10

T1: 45

G1: 13 G2: 41

G3: 2

GEM

1000 mg weekly for 8 weeks followed by 10 monthly instillations (a total of 1 year)

1 year

MMC

40 mg weekly for 8 weeks followed by 10 monthly instillations (a total of 1 year)

Raffaele 2010 [20]

109

93/16

GEM: 64.9 ± 10.5

MMC: 67.9 ± 10.2

NMIBC

Ta: 72

T1: 37

G1: 25

G2: 55

G3: 29

GEM

2000 mg weekly for 6 weeks followed by 10 monthly infusion during the first year

36 months

MMC

40 mg weekly for 4 weeks followed by 10 monthly infusion during the first year

  1. M Male, F Female, NMIBC Non-muscle invasive bladder cancer, GEM Gemcitabine, MMC Mitomycin, NA Not Available (Insufficient Information Provided)